High transporters on chronic peritoneal dialysis are challenged by increased protein losses, high glucose absorption with associated metabolic abnormalities, and poor ultrafiltration. Furthermore, the relative risk of mortality and technique failure is higher in high transporters than in patients of other transport types. An approach for satisfactory management of such patients on peritoneal dialysis (PD) has not been clearly demonstrated.
NolphK.D., MactierR., KhannaR., TwardowskiZ.J., MooreH., McGaryT.The kinetics of ultrafiltration during peritoneal dialysis: The role of lymphatics.Kidney Int1987; 32: 219–26.
ChurchillD.N., ThorpeK.E., NolphK.D., KeshaviahP.R., OreopoulosD.G., PageD., for the CANUSA peritoneal dialysis study group. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients.J Am Soc Nephrol1998; 9: 1285–92.
6.
BlakeP.G., AbrahamG., SomoloskK., IzzatS., WeissgartenJ., OreopoulosD.G.Changes in peritoneal membrane transport rates in patients on long term CAPD. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1989; 5: 3–7.
7.
NolphK.D.A survey of ultrafiltration in continuous ambulatory peritoneal dialysis. An international cooperative study. Third report. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in CAPD.Toronto: Peritoneal Dialysis Bulletin, 1985; 1: 79–86.
8.
NakayamaM., KawaguchiY., YamadaK., HasegawaT., TakazoeK., KatohN.Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int1997; 51: 182–6.
9.
MoriishiM., KawanishiH., KatsuniM., HaradaY., SakikuboE., MatsumotoT.Peritoneal resting in long term peritoneal dialysis patients [Abstract].Perit Dial Int2000; 20(Suppl 1): S11.
10.
Van BiesenW., WaterloosM., VogeleereP., NaggiA., LameireN.Use of chondroitin sulfate as an additive to glucose-containing dialysate [Abstract].Perit Dial Int1999; 19(Suppl 1): S11.
11.
GokalR., MistryC.D., PeersE.M., and the Midas study group. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD.Perit Dial Int1995; 15: 226–30.
12.
BlakeP.G., FlowerdewG., BlakeR.M., OreopoulosD.G.Serum albumin in patients on continuous ambulatory peritoneal dialysis. Predictors and correlations with outcomes.J Am Soc Nephrol1993; 3(8): 1501–7.
13.
BurkartJ.M.Effect of peritoneal dialysis prescription and transport characteristics on nutritional status.Perit Dial Int1995; 15(5, Suppl): S20–35.
14.
MamounH., AnderstamB., LindholmB., SöderstenP., BergströmJ.Peritoneal dialysis solutions with glucose and amino acids suppress appetite in rats [Abstract].J Am Soc Nephrol1994; 5: 498.
15.
NolphK.D., MooreH.L., ProwantB.F., TwardowskiZ.J., KhannaR., GamboaS.Continuous ambulatory peritoneal dialysis with a high flux membrane. A preliminary report.ASAIO Trans1993; 39: M556–68.
16.
KathuriaP., MooreH.L., KhannaR., TwardowskiZ.J., GoelS., NolphK.D.Effect of dialysis modality and membrane transport characteristics on dialysate protein losses of patients on peritoneal dialysis.Perit Dial Int1997; 17: 449–54.
17.
DonateT., OliverA., FacundoC., MartinezJ., RodaM., BarceloP.Oral protein supplement efficacy in peritoneal dialysis (PD) patients (II) [Abstract].Perit Dial Int1999; 19(Suppl 1): S15.
18.
KoppleJ.D., BernardD., MessanaJ., SwartzR., BergströmJ., LindholmB.Treatment of malnourished CAPD patients with an amino acid based dialysate.Kidney Int1995; 47: 1148–57.
19.
KennedyM., KerrL., DasguptaM., ChangW., PerryD., JumpsenJ.Randomized clinical trial of intraperitoneal amino acid (IPAA) solution in a North American peritoneal dialysis center. Preliminary data [Abstract].Perit Dial Int1999; 19(Suppl 1): S19.
20.
KamatN., RazzakN., PatB., TurekD., LightP.D.Effect of oral supplementation of 8 grams mixed amino acids on serum albumin in hypoalbuminemic CAPD patients [Abstract].Perit Dial Int2000; 20(Suppl 1): S24.
21.
WangT., HeimbürgerO., WaniewskiJ., BergströmJ., LindholmB.Increased peritoneal permeability is associated with decreased fluid and small solute removal and higher mortality in CAPD patients.Nephrol Dial Transplant1998; 13(5): 1242–9.
22.
HeimbürgerO., StenvinkelP., BerglundL., TranæusA., LindholmB.Increased plasma lipoprotein (a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.Nephron1996; 72: 135–44.
23.
HeimbürgerO., JogestrandT., WangT., LindholmB., StenvinkelP.High peritoneal transport rate in patients starting PD is related to early signs of atherosclerosis [Abstract].Perit Dial Int1999; 19(Suppl 1): S7.
24.
ChuW.S., KimJ.K., YiH.A., KimY.H., LeeI.S., ChungS.H.Peritoneal membrane hyperpermeability is an independent risk factor for CAPD mortality [Abstract].Perit Dial Int1999; 19(Suppl 1): S51.
25.
Cueto–ManzanoA.M., Correa–RotterR.Is high peritoneal transport rate a risk factor for CAPD mortality? [Abstract].Perit Dial Int1999; 19(Suppl 1): S52.
26.
WuC.H., HuangC.C., HuangJ.Y., WuM.S., LeuM.L.High flux peritoneal membrane is a risk factor in survival of CAPD treatment. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1996; 12: 105–9.
27.
DaviesS.J., PhillipsL., RussellG.I.Peritoneal solute transport predicts survival on CAPD independently of residual renal function.Nephrol Dial Transplant1998; 13: 962–8.
HungK.Y., LinT.J., TsaiT.J., ChenW.Y.Impact of peritoneal membrane transport on technique failure and patient survival in a population on automated peritoneal dialysis.ASAIO J1999; 45(6): 568–73.
32.
FriedL., BernardiniB., PirainoB.APD does not improve outcomes in high transporters [Abstract].Perit Dial Int2000; 20(Suppl 1): S64.
33.
HeafJ.CAPD adequacy and dialysis morbidity: Detrimental effects of a high peritoneal equilibration rate.Ren Fail1995; 17: 575–87.
34.
MistryC.D., GokalR., PeersE., and the Midas Study Group. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD.Kidney Int1994; 46: 496–503.
35.
HoweA., SeniorH., BrownE.A.Use of icodextrin: Could it extend time on PD? [Abstract].Perit Dial Int1999; 19(Suppl 1): S54.
36.
WilkieM.E., PlantM.J., EdwardsL., BrownC.B.Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival.Perit Dial Int1997; 17: 84–6.
37.
WoodrowG., StablesG., OldroydB., GibsonJ., TurneyJ.H., BrownjohnA.M.Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis.Nephrol Dial Transplant1999; 14: 1530–5.
38.
PosthumaN., ter WeeP.M., VerbrughH.A., OeP.L., PeersE., SayersJ.Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance.Nephrol Dial Transplant1999; 12: 550–3.
39.
BajoM.A., SelgasR., HeviaC., CastroM.J., AguileraA., MillanI.Icodextrin 7.5% dialysate for diurnal exchange in patients treated with CCPD [Abstract].Perit Dial Int1999; 19(Suppl 1): S49.
40.
BajoM.A., SelgasR., CastroM.A., CastroM.J., Del PesoG., AguileraA.Effect of icodextrin on mesothelial cell growth in culture [Abstract].Perit Dial Int2000; 20(Suppl 1): S55.
41.
MartisL., TopleyN., HolmesC.J.Conventional and newer peritoneal dialysis solutions. In: OwenW.F., PereiraJ.G., SayeghM.H., eds. Dialysis and transplantation: A companion to Brenner and Rector's The kidney.Philadelphia: W.B. Saunders Company;2000: 179–98.
42.
EmersonP.F., RuanJ., McLaughlinB.E., KeshaviahP.R., DeLeoM.A., PiscopoD.Effect of low-frequency ultrasound on peritoneal transport in rabbits. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications, 1997; 13: 77–80.
43.
ChaimovitzC., ZlotnikM., Ben–DavidA., ZichermanY.Extracorporeal abdominal vibration as a method for improving solute and fluid transport in peritoneal dialysis [Abstract].Perit Dial Int1999; 19(Suppl 1): S14.
